Krystal Biotech (KRYS) to Release Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) will be announcing its earnings results before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of $0.50 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The company had revenue of $45.25 million for the quarter, compared to the consensus estimate of $47.37 million. Krystal Biotech’s quarterly revenue was up 452400.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.76) EPS. On average, analysts expect Krystal Biotech to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Krystal Biotech Stock Performance

KRYS opened at $191.94 on Friday. The stock has a market capitalization of $5.48 billion, a P/E ratio of 102.64 and a beta of 0.84. The company’s 50-day simple moving average is $185.14 and its two-hundred day simple moving average is $163.56. Krystal Biotech has a 52-week low of $93.95 and a 52-week high of $219.34.

Wall Street Analyst Weigh In

KRYS has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a research note on Monday, May 6th. Stifel Nicolaus restated a “buy” rating and set a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and a consensus price target of $177.63.

Insider Transactions at Krystal Biotech

In other news, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).